Stock EUCI EUROCINE VACCINES AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eurocine Vaccines AB

Equities

EUCI

SE0015382155

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
0.0492 SEK +8.37% Intraday chart for Eurocine Vaccines AB -4.65% +6.96%
02-28 Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
02-15 Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024. CI

Valuation

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Capitalization 1 103.5 11.04 94.74 29.69 22.58 9.088
Enterprise Value (EV) 1 93.84 6.084 62.81 15.83 8.346 8.045
P/E ratio -2.19 x -0.61 x -4 x -1.63 x -0.93 x -0.41 x
Yield - - - - - -
Capitalization / Revenue - - - 64,677,020 x 322,583,943 x 1,817,586,800 x
EV / Revenue - - - 34,478,763 x 119,226,800 x 1,608,986,800 x
EV / EBITDA - - - - - -
EV / FCF -3.2 x -0.5 x -11.4 x -0.51 x 2.03 x -0.65 x
FCF Yield -31.2% -200% -8.77% -198% 49.2% -153%
Price to Book 11.3 x 8.15 x 3.15 x 0.93 x 1.45 x 2.83 x
Nbr of stocks (in thousands) 675 849 7,895 7,895 17,370 27,792
Reference price 2 153.4 13.00 12.00 3.760 1.300 0.3270
Announcement Date 28/11/18 27/11/19 25/11/20 17/11/21 29/11/22 28/11/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net sales - - - 0.459 0.07 0.005
EBITDA - - - - - -
EBIT 1 -42.48 -20.87 -8.907 -18.25 -20.15 -18.35
Operating Margin - - - -3,975.6% -28,785.71% -367,080%
Earnings before Tax (EBT) 1 -42.48 -21.12 -9.219 -18.25 -20.15 -18.35
Net income 1 -42.48 -21.12 -9.219 -18.25 -20.15 -18.35
Net margin - - - -3,976.91% -28,791.43% -367,000%
EPS 2 -70.00 -21.45 -3.000 -2.312 -1.400 -0.8000
Free Cash Flow 1 -29.29 -12.15 -5.506 -31.28 4.11 -12.3
FCF margin - - - -6,814.32% 5,871.07% -245,905%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 28/11/18 27/11/19 25/11/20 17/11/21 29/11/22 28/11/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 9.67 4.95 31.9 13.9 14.2 1.04
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -29.3 -12.1 -5.51 -31.3 4.11 -12.3
ROE (net income / shareholders' equity) -249% -337% -55% -58.9% -84.9% -195%
ROA (Net income/ Total Assets) -128% -147% -29.4% -33.4% -46.2% -94.2%
Assets 1 33.15 14.41 31.35 54.58 43.65 19.49
Book Value Per Share 2 13.60 1.600 3.810 4.040 0.9000 0.1200
Cash Flow per Share 2 14.30 2.330 4.040 1.760 0.8200 0.0400
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 28/11/18 27/11/19 25/11/20 17/11/21 29/11/22 28/11/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EUROCINE VACCINES AB Stock Eurocine Vaccines AB
+6.96% 882K
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-6.26% 11.42B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EUCI Stock
  4. Financials Eurocine Vaccines AB